Skip to main content
Top
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Cervical Cancer | Research

Updating approach for lexicographic optimization-based planning to improve cervical cancer plan quality

Authors: Paolo Caricato, Sara Trivellato, Roberto Pellegrini, Gianluca Montanari, Martina Camilla Daniotti, Bianca Bordigoni, Valeria Faccenda, Denis Panizza, Sofia Meregalli, Elisa Bonetto, Peter Voet, Stefano Arcangeli, Elena De Ponti

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Background

To investigate the capability of a not-yet commercially available fully automated lexicographic optimization (LO) planning algorithm, called mCycle (Elekta AB, Stockholm, Sweden), to further improve the plan quality of an already-validated Wish List (WL) pushing on the organs-at-risk (OAR) sparing without compromising target coverage and plan delivery accuracy.

Material and Methods

Twenty-four mono-institutional consecutive cervical cancer Volumetric-Modulated Arc Therapy (VMAT) plans delivered between November 2019 and April 2022 (50 Gy/25 fractions) have been retrospectively selected. In mCycle the LO planning algorithm was combined with the a-priori multi-criterial optimization (MCO). Two versions of WL have been defined to reproduce manual plans (WL01), and to improve the OAR sparing without affecting minimum target coverage and plan delivery accuracy (WL02). Robust WLs have been tuned using a subset of 4 randomly selected patients. The remaining plans have been automatically re-planned by using the designed WLs. Manual plans (MP) and mCycle plans (mCP01 and mCP02) were compared in terms of dose distributions, complexity, delivery accuracy, and clinical acceptability. Two senior physicians independently performed a blind clinical evaluation, ranking the three competing plans. Furthermore, a previous defined global quality index has been used to gather into a single score the plan quality evaluation.

Results

The WL tweaking requests 5 and 3 working days for the WL01 and the WL02, respectively. The re-planning took in both cases 3 working days. mCP01 best performed in terms of target coverage (PTV V95% (%): MP 98.0 [95.6–99.3], mCP01 99.2 [89.7–99.9], mCP02 96.9 [89.4–99.5]), while mCP02 showed a large OAR sparing improvement, especially in the rectum parameters (e.g., Rectum D50% (Gy): MP 41.7 [30.2–47.0], mCP01 40.3 [31.4–45.8], mCP02 32.6 [26.9–42.6]). An increase in plan complexity has been registered in mCPs without affecting plan delivery accuracy. In the blind comparisons, all automated plans were considered clinically acceptable, and mCPs were preferred over MP in 90% of cases. Globally, automated plans registered a plan quality score at least comparable to MP.

Conclusions

This study showed the flexibility of the Lexicographic approach in creating more demanding Wish Lists able to potentially minimize toxicities in RT plans.
Appendix
Available only for authorised users
Literature
3.
go back to reference Heijmen B, Voet P, Fransen D, Penninkhof J, Milder M, Akhiat H, Bonomo P, Casati M, Georg D, Goldner G, Henry A, Lilley J, Lohr F, Marrazzo L, Pallotta S, Pellegrini R, Seppenwoolde Y, Simontacchi G, Steil V, Stieler F, Wilson S, Breedveld S. Fully automated, multi-criterial planning for volumetric modulated arc therapy- an international multi-center validation for prostate cancer. Radiother Oncol. 2018;128:343–8.CrossRefPubMed Heijmen B, Voet P, Fransen D, Penninkhof J, Milder M, Akhiat H, Bonomo P, Casati M, Georg D, Goldner G, Henry A, Lilley J, Lohr F, Marrazzo L, Pallotta S, Pellegrini R, Seppenwoolde Y, Simontacchi G, Steil V, Stieler F, Wilson S, Breedveld S. Fully automated, multi-criterial planning for volumetric modulated arc therapy- an international multi-center validation for prostate cancer. Radiother Oncol. 2018;128:343–8.CrossRefPubMed
9.
go back to reference Fogliata A, Belosi F, Clivio A, Navarria P, Nicolini G, Scorsetti M, Vanetti E, Cozzi L. On the pre-clinical validation of a commercial model-based optimisation engine: application to volumetric arc therapy for patients with lung or prostate cancer. Radiother Oncol. 2014;113:385–91.CrossRefPubMed Fogliata A, Belosi F, Clivio A, Navarria P, Nicolini G, Scorsetti M, Vanetti E, Cozzi L. On the pre-clinical validation of a commercial model-based optimisation engine: application to volumetric arc therapy for patients with lung or prostate cancer. Radiother Oncol. 2014;113:385–91.CrossRefPubMed
10.
go back to reference Lian J, Yuan L, Ge Y, Chera BS, Yoo DP, Chang S, Yin FF, Wu JQ. Modeling the dosimetry of organ-at-risk in head and neck IMRT planning: an inter-technique and inter-institutional study. Med Phys. 2013;40:1217041–9.CrossRef Lian J, Yuan L, Ge Y, Chera BS, Yoo DP, Chang S, Yin FF, Wu JQ. Modeling the dosimetry of organ-at-risk in head and neck IMRT planning: an inter-technique and inter-institutional study. Med Phys. 2013;40:1217041–9.CrossRef
12.
go back to reference Marrazzo L, Meattini I, Arilli C, Calusi S, Casati M, Talamonti C, Livi L, Pallotta S. Auto-planning for VMAT accelerated partial breast irradiation. Radiother Oncol. 2019;132:85–92.CrossRefPubMed Marrazzo L, Meattini I, Arilli C, Calusi S, Casati M, Talamonti C, Livi L, Pallotta S. Auto-planning for VMAT accelerated partial breast irradiation. Radiother Oncol. 2019;132:85–92.CrossRefPubMed
14.
go back to reference Craft D, Bortfeld TR. How many plans are needed in an IMRT multi-objective plan database? Phys Med Biol. 2008;53:2785–96.CrossRefPubMed Craft D, Bortfeld TR. How many plans are needed in an IMRT multi-objective plan database? Phys Med Biol. 2008;53:2785–96.CrossRefPubMed
15.
go back to reference Monz M, Bortfeld TR, Kufer KH, Thieke C. Pareto navigation-algorithmic foundtion of interactive multi-criteria IMRT planning. Phys Med Biol. 2008;53:985–98.CrossRefPubMed Monz M, Bortfeld TR, Kufer KH, Thieke C. Pareto navigation-algorithmic foundtion of interactive multi-criteria IMRT planning. Phys Med Biol. 2008;53:985–98.CrossRefPubMed
16.
go back to reference Nakamura K, Okuhata K, Tamura M, Otsuka M, Kubo K, Ueda Y, Nakamura Y, Nakamatsu K, Tanooka M, Monzen H, Nishimura Y. An updating approach for knowledge-based planning models to improve plan quality and variability in volumetric-modulated arc therapy for prostate cancer. J Appl Clin Med Phys. 2021;22(9):113–22.CrossRefPubMedPubMedCentral Nakamura K, Okuhata K, Tamura M, Otsuka M, Kubo K, Ueda Y, Nakamura Y, Nakamatsu K, Tanooka M, Monzen H, Nishimura Y. An updating approach for knowledge-based planning models to improve plan quality and variability in volumetric-modulated arc therapy for prostate cancer. J Appl Clin Med Phys. 2021;22(9):113–22.CrossRefPubMedPubMedCentral
17.
go back to reference Hundvin JA, Fjellanger K, Pettersen HES, Nygaard B, Revheim K, Sulen TH, Ekanger C, Hysing LB. Clinical iterative model development improves knowledge-bassed plan quality for high-risk prostate cancer with four integrated dose levels. Acta Oncol. 2021;60(2):237–44.CrossRefPubMed Hundvin JA, Fjellanger K, Pettersen HES, Nygaard B, Revheim K, Sulen TH, Ekanger C, Hysing LB. Clinical iterative model development improves knowledge-bassed plan quality for high-risk prostate cancer with four integrated dose levels. Acta Oncol. 2021;60(2):237–44.CrossRefPubMed
18.
go back to reference Ueda Y, Miyazaki M, Sumida I, Ohira S, Tamura M, Monzen H, Tsuru H, Inui S, Isono M, Ogawa K, Teshima T. Knowledge-based planning for oesophageal cancers using a model trained with plans from a different treatment planning system. Acta Oncol. 2020;59(3):274–83.CrossRefPubMed Ueda Y, Miyazaki M, Sumida I, Ohira S, Tamura M, Monzen H, Tsuru H, Inui S, Isono M, Ogawa K, Teshima T. Knowledge-based planning for oesophageal cancers using a model trained with plans from a different treatment planning system. Acta Oncol. 2020;59(3):274–83.CrossRefPubMed
19.
go back to reference Bijman R, Sharfo AW, Rossi L, Breedveld S, Heijmen BJM. Pre-clinical validation of a novel system for fully-automated treatment planning. Radiother Oncol. 2021;158:253–61.CrossRefPubMed Bijman R, Sharfo AW, Rossi L, Breedveld S, Heijmen BJM. Pre-clinical validation of a novel system for fully-automated treatment planning. Radiother Oncol. 2021;158:253–61.CrossRefPubMed
22.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOSCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOSCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
24.
go back to reference Potter R, Tanderup K, Kirisits C, de Leeuw A, Kurchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B, Hoskin P, Bruheim K, Rai B, Huang F, Van Limbergen E, Schmid M, Nesvacil N, Sturdza A, Fokdal L, Jensen NBK, Georg D, Assenholt M, Seppenwoolde Y, Nomden C, Fortin I, Chopra S, van der Heide U, Rumpold T, Lindegaard JC, Jürgenliemk-Schulz I. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48–60.PubMedPubMedCentral Potter R, Tanderup K, Kirisits C, de Leeuw A, Kurchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B, Hoskin P, Bruheim K, Rai B, Huang F, Van Limbergen E, Schmid M, Nesvacil N, Sturdza A, Fokdal L, Jensen NBK, Georg D, Assenholt M, Seppenwoolde Y, Nomden C, Fortin I, Chopra S, van der Heide U, Rumpold T, Lindegaard JC, Jürgenliemk-Schulz I. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48–60.PubMedPubMedCentral
25.
go back to reference ICRU, ICRU Report 62, Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU 50), International Commission on Radiation Units and Measurements, Bethesda, Md, 1999. ICRU, ICRU Report 62, Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU 50), International Commission on Radiation Units and Measurements, Bethesda, Md, 1999.
26.
go back to reference Buckey CR, Swanson GP, Stathakis S, Papanikolaou N. Optimizing prostate intensity-modulated radiation therapy (IMRT): Do stricter constraints produce better dosimetric results? European J Clin Med Oncol. 2010;2(2):139–44. Buckey CR, Swanson GP, Stathakis S, Papanikolaou N. Optimizing prostate intensity-modulated radiation therapy (IMRT): Do stricter constraints produce better dosimetric results? European J Clin Med Oncol. 2010;2(2):139–44.
31.
go back to reference Landis JR, Koch GG. The measurment of observer agreement fo categorical data. Biometrics. 1977;33:159–74.CrossRefPubMed Landis JR, Koch GG. The measurment of observer agreement fo categorical data. Biometrics. 1977;33:159–74.CrossRefPubMed
33.
go back to reference Franco F, Di Napoli A. Valutazione della concordanza tra misurazioni di carattere di tipo quantitativo: il metodo di Bland- Altman. G Tec Nefrol Dial. 2017;29:56–61. Franco F, Di Napoli A. Valutazione della concordanza tra misurazioni di carattere di tipo quantitativo: il metodo di Bland- Altman. G Tec Nefrol Dial. 2017;29:56–61.
34.
go back to reference Voet PWJ, Dirkx MLP, Breedveld S, Fransen D, Levendag PC, Heijmen BJM. Toward fully automated multicriterial plan generation: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2013;85:866–72.CrossRefPubMed Voet PWJ, Dirkx MLP, Breedveld S, Fransen D, Levendag PC, Heijmen BJM. Toward fully automated multicriterial plan generation: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2013;85:866–72.CrossRefPubMed
36.
go back to reference Voet PWJ, Dirkx MLP, Breedveld S, Al-Mamgani A, Incrocci L, Heijmen BJM. Fully automated volumetric modulated arc therapy plan generation for prostate cancer patients. Int J Radiat Oncol Biol Phys. 2014;88:1175–9.CrossRefPubMed Voet PWJ, Dirkx MLP, Breedveld S, Al-Mamgani A, Incrocci L, Heijmen BJM. Fully automated volumetric modulated arc therapy plan generation for prostate cancer patients. Int J Radiat Oncol Biol Phys. 2014;88:1175–9.CrossRefPubMed
37.
go back to reference Fiandra C, Rossi L, Alparone A, Zara S, Vecchi C, Sardo A, Bartoncini S, Loi G, Pisani C, Gino E, Redda MGR, Deotto GM, Tini P, Comi S, Zerini D, Ametrano G, Borzillo V, Strigari L, Strolin S, Savini A, Romeo A, Reccanello S, Rumeileh IA, Ciscognetti N, Guerrisi F, Balestra G, Ricardi U, Heijmen B. Automatic genetic planning for volumteric modulated arc therapy: A large multi-centre validation for prostate cancer. Radiother Oncol. 2020;148:126–32.CrossRefPubMed Fiandra C, Rossi L, Alparone A, Zara S, Vecchi C, Sardo A, Bartoncini S, Loi G, Pisani C, Gino E, Redda MGR, Deotto GM, Tini P, Comi S, Zerini D, Ametrano G, Borzillo V, Strigari L, Strolin S, Savini A, Romeo A, Reccanello S, Rumeileh IA, Ciscognetti N, Guerrisi F, Balestra G, Ricardi U, Heijmen B. Automatic genetic planning for volumteric modulated arc therapy: A large multi-centre validation for prostate cancer. Radiother Oncol. 2020;148:126–32.CrossRefPubMed
39.
go back to reference Castriconi R, Fiorino C, Passoni P, Broggi S, Di Muzio NG, Cattaneo GM, Calandrino R. Knowledge-based automatic optimization of adaptive early-regression-guided VMAT for rectal cancer. Physica Med. 2020;70:58–64.CrossRef Castriconi R, Fiorino C, Passoni P, Broggi S, Di Muzio NG, Cattaneo GM, Calandrino R. Knowledge-based automatic optimization of adaptive early-regression-guided VMAT for rectal cancer. Physica Med. 2020;70:58–64.CrossRef
40.
go back to reference Wortel G, Eekhout D, Lamers E, van der Bel R, Kiers K, Wiersma T, Janssen T, Damen E. Characterization of automatic treatment planning approaches in radiotherapy. Phys Imag Radiat Oncol. 2021;19:60–5.CrossRef Wortel G, Eekhout D, Lamers E, van der Bel R, Kiers K, Wiersma T, Janssen T, Damen E. Characterization of automatic treatment planning approaches in radiotherapy. Phys Imag Radiat Oncol. 2021;19:60–5.CrossRef
Metadata
Title
Updating approach for lexicographic optimization-based planning to improve cervical cancer plan quality
Authors
Paolo Caricato
Sara Trivellato
Roberto Pellegrini
Gianluca Montanari
Martina Camilla Daniotti
Bianca Bordigoni
Valeria Faccenda
Denis Panizza
Sofia Meregalli
Elisa Bonetto
Peter Voet
Stefano Arcangeli
Elena De Ponti
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00800-5

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine